Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edesa Biotech, Inc.SBOT · Entity 7223 | Director | March 12, 2019 | March 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edesa Biotech, Inc.
Report date March 12, 2019 · Filed March 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2026-03-12 | Direct | 357 |
Reported balance
After 2019-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-12 · Grant · Acquired 357 · Balance 357 F1: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2020 and as to the remaining one-third on September 12, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2020 and as to the remaining one-third on September 12, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2019 Filed Mar 13, 2019 23:36 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 357 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001144204-19-013780 · tv516189_4.xml · derivative · entry 1 Aghib Deborah F. · CIK 0001727655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357 Underlying: Common Shares · 357 shares Expires 2026-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2020 and as to the remaining one-third on September 12, 2020. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:22 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014759 · tv488525_4.xml · derivative · entry 1 Aghib Deborah F. · CIK 0001727655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 13:46 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001144204-18-003570 · tv483951_4.xml · derivative · entry 1 Aghib Deborah F. · CIK 0001727655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2025-01-23 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third on January 23, 2019, as to one-third on January 23, 2020 and as to the remaining one-third on January 23, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.